ALT Nasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD ... Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and ...According to 6 stock analysts, the average 12-month stock price forecast for Altimmune stock is $17, which predicts an increase of 494.41%. The lowest target is $6.00 and the highest is $26. On average, analysts rate Altimmune stock as a strong buy.Shares of Altimmune ( ALT -0.99%) were down by 15% as of 3:27 p.m. EDT on Wednesday. The biotech announced before the market opened that it would present preclinical data for ALT-801 in treating ...Discover historical prices for ALT stock on Yahoo Finance. View daily, weekly or monthly format back to when Altimmune, Inc. stock was issued.Altimmune, Inc. is a clinical-stage biopharmaceutical company developing intranasal vaccines and immune modulating therapies. See, if ALT stock is a buy on upcoming catalysts in Q2-2021.Find the latest Altimmune, Inc. (ALT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Altimmune, Inc. Common Stock (ALT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ALT U.S.: Nasdaq Altimmune Inc. Watch list After Hours Last Updated: Sep 8, 2023 4:04 p.m. EDT Delayed quote $ 2.4897 0.04 1.62% After Hours Volume: 4.69K Advanced Charting Volume: 604.54K 65 Day...Jun 23, 2023 at 8:30 AM CEST. EASL International Liver Congress™ 2023. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial.View Altimmune, Inc ALT investment & stock information. Get the latest Altimmune, Inc ALT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Altimmune, Inc. Common Stock (ALT) Real-Time Quotes | Nasdaq. Add to Portfolio. ALT ALT REAL TIME. ALT Real-Time Quotes. 1D. 5D 1M 6M YTD 1Y 5Y MAX. Last Five Real-Time Trades. View Latest Real... Complete Altimmune Inc. stock information by Barron's. View real-time ALT stock price and news, along with industry-best analysis.Altimmune. stock last closed at $2.51, down 5.28% from the previous day, and has decreased 88.12% in one year. It has underperformed other stocks in the Biotechnology industry by 0.56 percentage points. Altimmune stock is currently +7.26% from its 52-week low of $2.34, and -88.75% from its 52-week high of $22.32.Altimmune. stock last closed at $2.51, down 5.28% from the previous day, and has decreased 88.12% in one year. It has underperformed other stocks in the Biotechnology industry by 0.56 percentage points. Altimmune stock is currently +7.26% from its 52-week low of $2.34, and -88.75% from its 52-week high of $22.32.GAITHERSBURG, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has closed its offering of approximately 15,656 shares of Series B convertible preferred stock and warrants.According to the issued ratings of 6 analysts in the last year, the consensus rating for Altimmune stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for ALT. The average twelve-month price prediction for Altimmune is $17.00 with a high price target of $26.00 and a low price target of $6.00.What is the target price for Altimmune (ALT) stock? A. The latest price target for Altimmune ( NASDAQ: ALT) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a ...52-Week Range $2.34 - $21.62. Previous Close $2.46. Volume 120.19K. Average Volume (3M) 1.67M. Market Cap. $128.03M. Enterprise Value N/A. Total Cash (Recent Filing) $160.00M. Total Debt (Recent Filing) $4.17M.On average, Wall Street analysts predict. that Altimmune's share price could reach $12.75 by Aug 14, 2024. The average Altimmune stock price prediction forecasts a potential upside of 388.51% from the current ALT share price of $2.61.Jun 23, 2023 at 8:30 AM CEST. EASL International Liver Congress™ 2023. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial.Complete Altimmune Inc. stock information by Barron's. View real-time ALT stock price and news, along with industry-best analysis.What is the target price for Altimmune (ALT) stock? A. The latest price target for Altimmune ( NASDAQ: ALT) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a ...On average, Wall Street analysts predict. that Altimmune's share price could reach $12.75 by Aug 14, 2024. The average Altimmune stock price prediction forecasts a potential upside of 388.51% from the current ALT share price of $2.61.Altimmune, Inc. ( NASDAQ: ALT) is a great speculative biotech play to look into. That's because there are 3 data readouts expected in the 2nd half of 2022. The two more notable ones would be from ...Track Altimmune Inc (ALT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAltimmune Inc (NASDAQ: ALT) shares are falling Wednesday morning. The company announced topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver ...View Altimmune, Inc ALT investment & stock information. Get the latest Altimmune, Inc ALT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Here's Why Altimmune Stock Is Surging Today. 502%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 502% . S&P 500 Returns. 130%.grp 6
Altimmune stock slumps ~35% amid phase 2 trial data of obesity drug pemvidutide SA News Tue, Mar. 21 13 Comments. Altimmune GAAP EPS of -$0.43 beats by $0.11 SA News Tue, Feb. 28.Mar. 21, 2023, 08:57 AM. Shares of clinical-stage biopharmaceutical company Altimmune Inc (NASDAQ:ALT) are trading lower Tuesday after the company announced results from an interim analysis of an ...Altimmune share price volatility. Over the last 12 months, Altimmune's shares have ranged in value from as little as $2.95 up to $23.49. A popular way to gauge a stock's volatility is its "beta". Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is -0.083.Altimmune (NASDAQ:ALT) had caught a strong bid back in H2 FY22 on the back of its developments in this regard. However, the rally didn't continue, and ALT stock since pared back to the downside ...910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450Altimmune (ALT) Set to Announce Earnings on Thursday marketbeat.com - May 5 at 10:04 AM: Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 finance.yahoo.com - May 4 at 7:58 AM: Altimmune, Inc. (ALT) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - April 24 at 9:15 AMALT U.S.: Nasdaq Altimmune Inc. Watch list After Hours Last Updated: Sep 8, 2023 4:04 p.m. EDT Delayed quote $ 2.4897 0.04 1.62% After Hours Volume: 4.69K Advanced Charting Volume: 604.54K 65 Day...Even after such a fantastic rally, Altimmune stock is ridiculously cheap. It has a market cap of just $617.44 million with a cash balance of $216 million, giving it an enterprise value of only ...Here's Why Altimmune Stock Is Surging Today. 513%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 513% . S&P 500 Returns. 132%.910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450audiochuck
Mar. 21, 2023, 08:57 AM. Shares of clinical-stage biopharmaceutical company Altimmune Inc (NASDAQ:ALT) are trading lower Tuesday after the company announced results from an interim analysis of an ...Trading Information Last Close 2.45 Sector Healthcare Industry Biotechnology Investment Style Small Value Day Range 2.41 – 2.49 Year Range 2.34 – 21.62 Market Cap 129.0817 Mil Volume / Avg...Altimmune, Inc. Common Stock (ALT) Real-Time Quotes | Nasdaq. Add to Portfolio. ALT ALT REAL TIME. ALT Real-Time Quotes. 1D. 5D 1M 6M YTD 1Y 5Y MAX. Last Five Real-Time Trades. View Latest Real... JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Altimmune ( ALT – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday at $3.38 ...Altimmune, Inc. Common Stock (ALT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Stock Quote & Chart Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage NASDAQ: ALT $2.45 Sep 8, 2023 4:00 PM EDT Change -0.01 (-0.41%) Volume 607,073 Today's Open $2.45 Previous Close $2.46 Today's High $2.49 Today's Low $2.41 52 Week High $21.62 52 Week Low $2.34 Data Provided by Refinitiv.According to 6 stock analysts, the average 12-month stock price forecast for Altimmune stock is $17, which predicts an increase of 494.41%. The lowest target is $6.00 and the highest is $26. On average, analysts rate Altimmune stock as a strong buy.Trading Information Last Close 2.45 Sector Healthcare Industry Biotechnology Investment Style Small Value Day Range 2.41 – 2.49 Year Range 2.34 – 21.62 Market Cap 129.0817 Mil Volume / Avg...ABOUT US. Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.yonkers honda
Approximately 50% of subjects achieved 10% weight loss or more and about 20% reached 15% weight loss or more. The safety trial showed 7.7% weight loss at week 12. President and CEO of Altimmune ...Altimmune has produced decent data in both NASH and obesity patients. Click here to see why ALT stock is a Hold.Based on short-term price targets offered by seven analysts, the average price target for Altimmune, Inc. comes to $19.57. The forecasts range from a low of $6.00 to a high of $35.00. The average ...Altimmune stock slumps ~35% amid phase 2 trial data of obesity drug pemvidutide SA News Tue, Mar. 21 13 Comments. Altimmune GAAP EPS of -$0.43 beats by $0.11 SA News Tue, Feb. 28.The Altimmune, Inc. stock price fell by -0.797% on the last day (Wednesday, 6th Sep 2023) from $2.51 to $2.49. During the last trading day the stock fluctuated 5.83% from a day low at $2.40 to a day high of $2.54. The price has fallen in 5 of the last 10 days and is down by -3.49% for this period. Volume has increased on the last day by 242 ...gorodenkoff. Altimmune (NASDAQ:ALT) said all three doses of its medicine pemvidutide met the main goal of a phase 1b trial by showing relative and absolute reductions in liver fat in patients with ...Altimmune's success in the peptide-based therapies market demonstrates its effectiveness as an alternative to biologics and small molecule medications. Find out why ALT stock is a Buy.Altimmune Inc, 910 Clopper Road Suite 201S, Gaithersburg, MD 20878 (240) 654-1450 [email protected]. Investors. Richard Eisenstadt Chief Financial OfficerAltimmune stock slumps ~35% amid phase 2 trial data of obesity drug pemvidutide SA News Tue, Mar. 21 13 Comments. Altimmune GAAP EPS of -$0.43 beats by $0.11 SA News Tue, Feb. 28.A. While ratings are subjective and will change, the latest Altimmune ( ALT) rating was a maintained with a price target of $20.00 to $15.00. The current price Altimmune ( ALT) is trading at is $3 ...PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases. November 17, 2016. PharmAthene Declares $2.91 Special Cash Dividend on Common Stock. November 16, 2016. PharmAthene Receives Final Payment from SIGA of $83.9 Million. November 4, 2016.Trading Information Last Close 2.45 Sector Healthcare Industry Biotechnology Investment Style Small Value Day Range 2.41 – 2.49 Year Range 2.34 – 21.62 Market Cap 129.0817 Mil Volume / Avg...venice italy map
Altimmune (NASDAQ: ALT) stock is losing value on Tuesday after the company released results from a clinical trial. That trial has to do with the company’s treatment for obesity. The bad news for ...Trading Information Last Close 2.45 Sector Healthcare Industry Biotechnology Investment Style Small Value Day Range 2.41 – 2.49 Year Range 2.34 – 21.62 Market Cap 129.0817 Mil Volume / Avg...GAITHERSBURG, Md. , Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Wells Fargo 2023Altimmune Inc, 910 Clopper Road Suite 201S, Gaithersburg, MD 20878 (240) 654-1450 [email protected]. Investors. Richard Eisenstadt Chief Financial OfficerAltimmune (NASDAQ:ALT) had caught a strong bid back in H2 FY22 on the back of its developments in this regard. However, the rally didn't continue, and ALT stock since pared back to the downside ...My top three picks for next year are Altimmune ( ALT -0.41%), Karuna Therapeutics ( KRTX -0.54%), and Viking Therapeutics ( VKTX 8.76%). Read on to find out more about these three growth-oriented ...Altimmune Inc (ALT) Stock Price & News - Google Finance Home ALT • NASDAQ Altimmune Inc Follow Share $2.45 After Hours: $2.43 (0.82%) -0.020 Closed: Sep 8, 5:34:23 PM GMT-4 · USD · NASDAQ ·...Altimmune Inc 9.09 0.17 (1.84%) Watch. 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. Altimmune Inc NASDAQ Updated Nov 25, 2022 9:58 PM.Altimmune share price volatility. Over the last 12 months, Altimmune's shares have ranged in value from as little as $2.95 up to $23.49. A popular way to gauge a stock's volatility is its "beta". Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is -0.083.A. While ratings are subjective and will change, the latest Altimmune ( ALT) rating was a maintained with a price target of $20.00 to $15.00. The current price Altimmune ( ALT) is trading at is $3 ...Discover historical prices for ALT stock on Yahoo Finance. View daily, weekly or monthly format back to when Altimmune, Inc. stock was issued.Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation ...Altimmune Inc (NASDAQ:ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges.; The Phase 1/2 trial for T-COVID ...Altimmune, Inc. (ALT) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 2.4600 -0.0300 (-1.20%) At close: 04:00PM EDT 2.4800 +0.02 (+0.81%) After hours: 04:14PM EDT 1d 5d 1m...Suspicious Activity Detected - TipRanks | Stock Market ...mila air purifier910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450My top three picks for next year are Altimmune ( ALT -0.41%), Karuna Therapeutics ( KRTX -0.54%), and Viking Therapeutics ( VKTX 8.76%). Read on to find out more about these three growth-oriented ...Altimmune Inc (NASDAQ:ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges.; The Phase 1/2 trial for T-COVID ...According to the issued ratings of 6 analysts in the last year, the consensus rating for Altimmune stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for ALT. The average twelve-month price prediction for Altimmune is $17.00 with a high price target of $26.00 and a low price target of $6.00.PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases. November 17, 2016. PharmAthene Declares $2.91 Special Cash Dividend on Common Stock. November 16, 2016. PharmAthene Receives Final Payment from SIGA of $83.9 Million. November 4, 2016.910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450Based on short-term price targets offered by seven analysts, the average price target for Altimmune, Inc. comes to $19.57. The forecasts range from a low of $6.00 to a high of $35.00. The average ...Complete Altimmune Inc. stock information by Barron's. View real-time ALT stock price and news, along with industry-best analysis.Altimmune Inc 9.09 0.17 (1.84%) Watch. 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. Altimmune Inc NASDAQ Updated Nov 25, 2022 9:58 PM.Trading Information Last Close 2.45 Sector Healthcare Industry Biotechnology Investment Style Small Value Day Range 2.41 – 2.49 Year Range 2.34 – 21.62 Market Cap 129.0817 Mil Volume / Avg...Altimmune (NASDAQ: ALT) stock is losing value on Tuesday after the company released results from a clinical trial. That trial has to do with the company’s treatment for obesity. The bad news for ...Altimmune stock fully deserves my B rating as a truly innovative developer of important medical solutions and treatments. This is more than a coronavirus company, but if you’re going to pick a ...The consensus 12-month price target for Altimmune reflected an upside potential of 169% compared to the stock's closing price on March 20, 2023. Those bullish views hinged in large part on the ...newberry observer
Altimmune share price volatility. Over the last 12 months, Altimmune's shares have ranged in value from as little as $2.95 up to $23.49. A popular way to gauge a stock's volatility is its "beta". Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is -0.083.Altimmune share price volatility. Over the last 12 months, Altimmune's shares have ranged in value from as little as $2.95 up to $23.49. A popular way to gauge a stock's volatility is its "beta". Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is -0.083.910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450Jun 23, 2023 at 8:30 AM CEST. EASL International Liver Congress™ 2023. Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial.910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450Altimmune (ALT) Set to Announce Earnings on Thursday marketbeat.com - May 5 at 10:04 AM: Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 finance.yahoo.com - May 4 at 7:58 AM: Altimmune, Inc. (ALT) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - April 24 at 9:15 AMAltimmune (NASDAQ:ALT) had caught a strong bid back in H2 FY22 on the back of its developments in this regard. However, the rally didn't continue, and ALT stock since pared back to the downside ...Mar. 21, 2023, 08:57 AM. Shares of clinical-stage biopharmaceutical company Altimmune Inc (NASDAQ:ALT) are trading lower Tuesday after the company announced results from an interim analysis of an ...Find real-time ALT - Altimmune Inc stock quotes, company profile, news and forecasts from CNN Business.sandata
Altimmune stock fully deserves my B rating as a truly innovative developer of important medical solutions and treatments. This is more than a coronavirus company, but if you’re going to pick a ...Approximately 50% of subjects achieved 10% weight loss or more and about 20% reached 15% weight loss or more. The safety trial showed 7.7% weight loss at week 12. President and CEO of Altimmune ...ALTIMMUNE : Piper Sandler Adjusts Altimmune's Price Target to $34 from $16, Keeps Overweight Rating 2021: MT ALTIMMUNE : B. Riley Raises Altimmune's PT to $27 from $21 Ahead of 12-Week Weight Loss Readout from ALT-801 Study, Keeps Buy Rating 2021: MTCompany Profile. Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.